GUARDANT HEALTH INC (GH) Forecast, Price Target & Analyst Ratings
NASDAQ:GH • US40131M1099
87.9025 USD
-2.59 (-2.86%)
Last: Mar 11, 2026, 10:00 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GUARDANT HEALTH INC (GH).
Forecast Snapshot
Consensus Price Target
$131.82
+ 49.96% Upside
Next Earnings Forecast
Release DateApr 28, 2026
PeriodQ1 / 2026
EPS Estimate-$0.78
Revenue Estimate287.65M
ChartMill Buy Consensus
85.63%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$131.82
Upside
+ 49.96%
From current price of $87.90 to mean target of $131.82, Based on 32 analyst forecasts
Low
$64.07
Median
$132.60
High
$189.00
Price Target Revisions
1 Month
6.95%
3 Months
30.87%
Price Target Summary
32 Wall Street analysts provided a forecast for the next 12 months for GH. The average price target is 131.82 USD. This implies a price increase of 49.96% is expected in the next year compared to the current price of 87.9025.
The average price target has been revised upward by 30.87% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.63%
GH was analyzed by 32 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about GH.
In the previous month the buy percentage consensus was at a similar level.
GH was analyzed by 32 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-24 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-20 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-20 | BTIG | Maintains | Buy -> Buy |
| 2026-02-20 | Stifel | Maintains | Buy -> Buy |
| 2026-02-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-20 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-02-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-20 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-02-20 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-17 | Baird | Initiate | Outperform |
| 2026-01-26 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-09 | Stifel | Maintains | Buy -> Buy |
| 2026-01-05 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-05 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2025-12-22 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-17 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-15 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-15 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-15 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-12-12 | BTIG | Maintains | Buy -> Buy |
| 2025-12-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-02 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-30 | BTIG | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 28, 2026
PeriodQ1 / 2026
EPS Estimate-$0.78
Revenue Estimate287.65M
Revenue Q2Q41.37%
EPS Q2Q5.43%
Number of Analysts26
Next Earnings Revisions
Revenue (1 Month)
2.65%
Revenue (3 Months)
3.05%
EPS (1 Month)
-9.51%
EPS (3 Months)
-18.15%
Next Earnings Summary
GH is expected to report earnings on 4/28/2026. The consensus EPS estimate for the next earnings is -0.78 USD and the consensus revenue estimate is 287.65M USD.
The next earnings revenue estimate has been revised upward by 3.05% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 563.948M 25.46% | 739.016M 31.04% | 982.021M 32.88% | 1.274B 29.73% | 1.627B 27.71% | 2.03B 24.77% | 2.565B 26.35% | 3.2B 24.76% | 3.591B 12.22% | 4.075B 13.48% | 4.478B 9.89% | |
| EBITDA YoY % growth | -521.844M -2.64% | -401.207M 23.12% | -397.512M 0.92% | -184.603M 53.56% | -63.673M 65.51% | 132.21M 307.64% | 332.18M 151.25% | 668.02M 101.10% | 1.07B 60.17% | 1.158B 8.22% | 1.214B 4.84% | |
| EBIT YoY % growth | -564.725M -3.73% | -443.594M 21.45% | -437.248M 1.43% | -344.959M 21.11% | -243.43M 29.43% | 18.754M 107.70% | 119.08M 534.96% | 509.32M 327.71% | 771.7M 51.52% | 963.56M 24.86% | 1.115B 15.72% | |
| Operating Margin | -100.14% | -60.02% | -44.53% | -27.08% | -14.96% | 0.92% | 4.64% | 15.92% | 21.49% | 23.65% | 24.90% | |
| EPS YoY % growth | -3.34 36.33% | -3.56 -6.59% | -3.36 5.62% | -2.51 25.37% | -1.59 36.62% | 0.72 145.28% | 1.19 66.05% | 4.87 307.76% | 6.57 34.88% | 7.31 11.29% | 7.95 8.73% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.78 5.43% | -0.70 12.11% | -0.58 21.71% | -0.50 50.19% | -0.66 15.32% | -0.56 20.90% | -0.42 27.56% | -0.39 20.90% | -0.24 63.92% | -0.22 61.11% |
| Revenue Q2Q % growth | 287.65M 41.37% | 314.13M 35.35% | 331.24M 24.90% | 346.82M 23.31% | 344.88M 19.90% | 377.96M 20.32% | 411.25M 24.15% | 422.18M 21.73% | 445.68M 29.23% | 481.53M 27.40% |
| EBITDA Q2Q % growth | -50.029M 50.37% | -45.288M 47.42% | -34.155M 50.72% | -35.525M 56.18% | -36.7M 26.64% | -22.041M 51.33% | -23.368M 31.58% | 331.145K 100.93% | N/A | N/A |
| EBIT Q2Q % growth | -104.748M 5.67% | -97.645M 8.24% | -82.228M 16.93% | -76.285M 36.85% | -90.705M 13.41% | -76.356M 21.80% | -58.413M 28.96% | -54.084M 29.10% | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
30.34%
EPS Next 5 Year
28.10%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
26.63%
Revenue Next 5 Year
26.20%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
32.67%
EBIT Next 5 Year
29.86%
GUARDANT HEALTH INC / GH Forecast FAQ
What is the average price target for GUARDANT HEALTH INC (GH) stock?
32 analysts have analysed GH and the average price target is 131.82 USD. This implies a price increase of 49.96% is expected in the next year compared to the current price of 87.9025.
What is the next earnings date for GH stock?
GUARDANT HEALTH INC (GH) will report earnings on 2026-04-28, after the market close.
What are the consensus estimates for GH stock next earnings?
The consensus EPS estimate for the next earnings of GUARDANT HEALTH INC (GH) is -0.78 USD and the consensus revenue estimate is 287.65M USD.
How many analysts cover GUARDANT HEALTH INC (GH) stock?
The number of analysts covering GUARDANT HEALTH INC (GH) is 32.